Chris Grant is a senior vice president at Kaiser Permanente and serves as a member of the senior executive management team. In addition to overseeing Corporate Development, Mergers and Acquisitions and Care Delivery Strategy, Grant is managing director of Kaiser Permanente’s venture capital group. Grant co-founded the investment program in 2000 and has overseen more than 50 investments in highly innovative medical technology companies. Kaiser Permanente’s successful venture investment function is designed to support the company's health care mission while generating venture capital rates of return. Grant has served as a board director or advisor to over a dozen medical technology and service companies.
Prior to the formation of the venture fund in 2000, Grant was responsible for creating, developing and managing a portfolio of new products and business lines for the organization. Before joining Kaiser Permanente in 1995, Grant held several positions on the Business Development and Financial Management Team of Rockwell International Corp. He served on Gov. Brown’s Job Creation Advisory Committee and currently serves on the boards of the East Bay Foundation for Health Education, the Pleasanton partnerships in Education Foundation and the Livermore Valley Performing Arts Council. He is a trustee of his local school district and serves as an advisor to the California Healthcare Foundation’s investment program and the Health and Science Department of Dominican University.
Grant has a bachelor’s degree in business from the University of California, Santa Barbara and has completed executive management programs at the Kenan-Flagler School of Business (University of North Carolina at Chapel Hill), as well as Venture Capital Institute undergraduate and graduate programs.
Bob was instrumental in establishing the Kaiser Permanente Venture Fund in 2000 and is responsible for managing the pipeline of new venture prospects, as well as leading investment evaluations and financing decisions. He is a manager or board observer for several portfolio companies and targets investments in imaging, lab/diagnostics, women's health and related therapeutics/devices. Prior to joining Kaiser Permanente in 1997, Bob pursued a career in banking at Wells Fargo and other financial institutions with responsibilities in treasury operations, performance planning/metrics, incentive compensation and finance training. He holds a MBA in Finance from the University of California at Berkeley and a Bachelor's Degree in Economics from the University of Washington. Bob has completed the executive management leadership program at the University of North Carolina and Venture Capital Institute graduate programs.
Dave has more than 17 years of experience, as an investor and investment banker, partnering with entrepreneurs to build innovative health care and technology businesses. He joined Kaiser Permanente Ventures in 2003 and helped build KP's investment program. He now manages the Fund's investment strategy and day to day activities. Prior to KP Ventures, Dave was a health care and software investment banker at J.P. Morgan, UBS, and Piper Jaffray.
He serves or served as a Board Director or Observer for several companies: Atheromed (sold to Volcano), Hemosphere (sold to Cryolife), MetricStream, Nursefinders (sold to Goldman Sachs), Omada Health, Proteus Digital Health, Pulmonx, Valeritas and Xanitos.
Dave is a graduate of St. John's University and earned a Master of Public Policy degree from Harvard University.
Sam brings over 15 years of experience working with healthcare companies to Kaiser Permanente Ventures. Prior to joining the group in 2011, he was an Executive-in-Residence and Vice President with Frazier Healthcare Ventures. At Frazier, Sam focused on venture and growth equity stage investments in the medical device and healthcare services sectors. Previously, Sam was in global management roles at Medtronic, Inc. in the US and Europe as well as with venture-backed start ups in the medical device and HCIT fields. He began his career as a management consultant in the healthcare services space with APM/CSC Healthcare.
Sam focuses on investments in medical device, healthcare services, and healthcare IT companies. He serves on the Board of Directors at iRhythm Technologies, Glumetrics, Nordic Consulting Partners and Vapotherm and is a Board Observer for DSI Renal and Health Catalyst.
Sam holds a B.A. in Public Policy from Stanford University and an MBA in Health Care Management from The Wharton School, University of Pennsylvania.
Jordan has extensive experience working with entrepreneurs and growth companies as a venture investor and strategy consultant at Bain & Company and Cambridge Strategic Management Group. Since joining Kaiser Permanente Ventures in 2006, Jordan has focused on investments in diagnostics and imaging, ophthalmology and drug-delivery devices, and health care information technology.
Jordan currently serves as a Board Director for Celula and a Board Observer to Astute Medical, BDNA, and Transcend Medical.
Jordan holds a Bachelor's Degree in History from Cornell University and an international MBA in Entrepreneurial Studies and Finance from the University of Chicago Graduate School of Business.
Prior to joining Kaiser Permanente Ventures, Jordan spent three years as the Director of Finance and Development for BUILD, an educational non-profit using entrepreneurship to inspire at-risk high-school students to go to college.
Hong is responsible for venture investment analysis, evaluation and transaction execution. Before Kaiser Permanente Ventures, Hong spend three years at Analysis Group, an economic, financial and strategy consulting firm, focusing on the health economics and strategy practice. At Analysis Group, Hong worked with pharmaceutical and biotechnology companies to help clients develop strategies and related evidence to support anticipated evidence based review, especially in the context of coverage and reimbursement determination. Prior to Analysis Group, Hong was a public health researcher with work spanning nutritional epidemiology, health economics, and outcomes data analysis. Hong received her BSc in Human Biology and BA in International Relations from Brown University and MPH in Health Management from Yale University.